



## Supporting Information

for

### **Anion exchange resins in phosphate form as versatile carriers for the reactions catalyzed by nucleoside phosphorylases**

Julia N. Artsemyeva, Ekaterina A. Remeeva, Tatiana N. Buravskaya,  
Irina D. Konstantinova, Roman S. Esipov, Anatoly I. Miroshnikov, Natalia M. Litvinko  
and Igor A. Mikhailopulo

*Beilstein J. Org. Chem.* **2020**, *16*, 2607–2622. [doi:10.3762/bjoc.16.212](https://doi.org/10.3762/bjoc.16.212)

### **Experimental details and NMR spectra of synthesized compounds**

## Table of Contents

1 – <b>Table SI-1:</b> $^1\text{H}$ NMR spectral data for nelarabine, kinetin riboside, and $N^6$ -benzyladenosine.....	S2
2 – <b>Table SI-2:</b> $^{13}\text{C}$ NMR spectral data for of nelarabine, kinetin riboside and $N^6$ -benzyladenosine.....	S3
3 – <b>SI-3.</b> $^1\text{H}$ NMR spectrum of nelarabine .....	S4
4 – <b>SI-4.</b> $^1\text{H}$ and $^{13}\text{C}$ NMR spectra of kinetin riboside.....	S5
5 – <b>SI-5.</b> Synthesis of $N^6$ -benzyladenoside and $^1\text{H}$ and $^{13}\text{C}$ NMR spectra .....	S7
6 – <b>SI-6.</b> Combined data on the enzymatic synthesis of nelarabine, kinetin riboside, $N^6$ -benzyladenosine and cladribine.S .....	S10
References.....	S12

**1 – Table SI – 1.** <sup>1</sup>H NMR spectral data for nelarabine, kinetin riboside, *N*<sup>6</sup>-benzyladenosine, and cladribine in DMSO-*d*<sub>6</sub> (δ<sub>TMS</sub>, ppm).


Compound	<i>H</i> -1'	<i>H</i> -2' (lower field resonance)	<i>H</i> -2'' (higher field resonance)	<i>H</i> -3'	<i>H</i> -4'	<i>H</i> -5'	<i>H</i> -5''	Others
Nelarabine	6.12 d	-	≈4.06 m	≈4.08	3.75 “q”	3.65 ddd	3.61 ddd	7.92 (s, H-8); 6.42 (s, 2H, N <sup>2</sup> H <sub>2</sub> ); 5.60 (d, 1H, <i>J</i> = 5.36, 2'-OH); 5.49 (d, 1H, <i>J</i> = 3.48, 3'-OH); 5.05 (t, 1H, <i>J</i> = 5.29, 5'-OH) 3.96 (s, 3H, OCH <sub>3</sub> )
Kinetin Riboside	5.96 d	4.68 dt	-	4.21 m	4.03 q	3.74 dt	3.62 ddd	8.45. (s, H-8); 8.31 (s, H-2) 7.60 (q, <i>J</i> = 0.7 & 1.65 Hz), 6.42 (q, <i>J</i> = 1.8 & 3.15 Hz,) & 6.29 (d, <i>J</i> = 3.0 Hz); (FF group) 8.38 (br. s, 6-NH) 5.50 (d, <i>J</i> <sub>2',OH</sub> = 6.20); 5.42 (q, <i>J</i> <sub>5',OH</sub> = 4.6 & 7.05; 5'-OH); 5.24 (d, <i>J</i> <sub>3',OH</sub> = 4.70; 3'-OH) 4.76 (br. s, 2H, -CH <sub>2</sub> -Ph)
<i>N</i> <sup>6</sup> -Benzyladenosine	5.89 d	4.61 “d”	-	4.15 br. m	3.96 q	3.67 dt	3.55 ddd	8.38. (s, H-8); 8.20 (s, H-2) 8.45 (br. s, 6-NH) 7.33 (d, ortho), 7.28 (td, meta) & 7.20 (tt, para); (Bzl) 5.43 (d, <i>J</i> <sub>2',OH</sub> = 6.20); 5.42 (q, <i>J</i> <sub>5',OH</sub> = 4.6 & 7.05; 5'-OH); 5.17 (d, <i>J</i> <sub>3',OH</sub> = 4.65; 3'-OH) 4.71 (br. s, 2H, -CH <sub>2</sub> -Ph)
Cladribine	6.38 d	2.66 ddd	2.30 ddd	4.45-4.36 m	3.88 dt	3.62 ddd	3.53dt	8.38 (s, H-8); 7.85 (br.s, NH <sub>2</sub> ) 5.34 (d, <i>J</i> = 4.2 Hz; C3'-OH) 4.98 (t, <i>J</i> = 5.6 Hz; C5'-OH)

**2 – Table SI – 2.**  $^{13}\text{C}$  NMR spectral data for nelarabine, kinetin riboside,  $N^6$ -benzyladenosine, and cladribine in  $\text{DMSO-}d_6$  ( $\delta_{\text{TMS}}$ , ppm).


Compound	Chemical shifts ( $\delta_{\text{TMS}}$ , ppm)									
	C1'	C2'	C3'	C4'	C5'	C2	C4	C5	C6	C8
Nelarabine <sup>a)</sup>	84.20 (83.35)	75.47 75.29	75.29 75.47	83.35 (84.20)	60.95	153.98	159.74	113.16	160.52	139.06
Kinetin Riboside <sup>b)</sup>	87.90	73.48	70.61	85.86	61.63	152.87	148.50	≈119.5	154.32	140.01
$N^6$ -Benzyladenosine <sup>c,d)</sup>	87.93	73.45	70.64	85.88	61.65	152.33	148.45	119.78	154.50	139.94
Cladribine	84.04	<sup>e)</sup>	71.19	88.43	62.14	157.44	150.55	118.65	157.28	140.30


- a)  $\text{OCH}_3$  54.05 ppm.
- b) The  $^{13}\text{C}$  resonances of KR ( $\delta_{\text{TMS}}$ , ppm): 141.81 [correlates with a proton (q,  $J$ 's = 0.70 and 1.65 Hz) at 7.60 ppm]; 110.43 [correlates with a proton (q,  $J$ 's = 1.80 and 3.15 Hz) at 6.42 ppm]; 106.63 (correlates with a proton (d,  $J$  = 3.0 Hz) at 6.29 ppm]; the C1-*ipso* of the FF ring appeared at 152.87 ppm and the  $\text{CH}_2$  resonance is at 36.53 ppm.
- c) The  $^{13}\text{C}$  resonances of BzlNH ( $\delta_{\text{TMS}}$ , ppm): 140.09 (*ipso*), 128.20 (*ortho*), 127.12 (*meta*), 126.60 (*para*), and 42.86 ( $\text{CH}_2$ ).
- d) The  $^{13}\text{C}$ -*ipso* resonance of the Bzl group is overlapped by the  $^{13}\text{C}$ -8 resonance.
- e) The resonance signal of C-2' is overlapped by DMSO

3 – SI-3. <sup>1</sup>H NMR spectrum of nelarabine in MeOD.



4 – SI-4. <sup>1</sup>H and <sup>13</sup>C NMR spectra of kinetin riboside in CD<sub>5</sub>OD.







**5 – SI-5.** Synthesis and  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of  $N^6$ -benzyladenoside in  $\text{DMSO-}d_6$ .

**$N^6$ -Benzyladenosine:** To a heterogeneous reaction mixture containing guanosine (425 mg, 1.5 mmol) and  $N^6$ -benzyladenine (225 mg, 1 mmol) in 140 mL of 5.0 mM K-phosphate buffer (pH 7.0) was added *E. coli* PNP (140 IU) and the mixture was gently stirred at 40 °C for 20 h (some quantity of the starting heterocyclic base remained in the reaction mixture according to TLC). Then, guanosine (0.14 g, 0.5 mmol) was added and the heating continued for 6 h and the reaction mixture was left overnight at 4 °C. The solution was decanted from the precipitate formed and evaporated to dryness, the residue was mixed with one tee spoon of  $\text{SiO}_2$  and put on the top of a standard column (2 × 22 cm) packed in DCE/MeOH 95:5 (vol). Elution with the same mixture of solvents gave 20 mg of  $N^6$ -benzyladenine and its riboside (0.22 g, yield 67%; purity 99.2% according to HPLC); mp 178-180 °C (from EtOH); UV ( $\text{H}_2\text{O}$ ):  $\lambda_{\text{max}}$  269 and 209 nm ( $\epsilon$  20,140 and 25,230),  $\lambda_{\text{min}}$  232 nm ( $\epsilon$  2,720).  $\lambda_{\text{max}}$  269 nm ( $\epsilon$  20,140); lit. data: (1) mp 182-183 °C (from EtOH); UV (EtOH),  $\lambda_{\text{max}}$  = 271 nm, ( $\epsilon$  4,290) [1]; (2) mp 177-179 °C (from EtOH)}. UV (MeOH):  $\lambda_{\text{max}}$  268 nm ( $\epsilon$  20,850);  $\lambda_{\text{min}}$  233 nm ( $\epsilon$  2,570) [2].







**6 – SI-6. Combined data on the enzymatic synthesis of nelarabine, kinetin riboside, N<sup>6</sup>-benzyladenosine, and cladribine.**

№	Product	Substrate(s)	Enzyme(s) (IU per 1 mmol of substrate)	Reactions condifions		Conver- sion (%)	Yield of pure product (%)	Refs
				Solution	Time (hrs) (Temp.;°C)			
1	Fludarabine	2F-Ade & Ara-C (1:1.4, mmol)	<i>E. coli</i> PNP (93.3) & cytidine deaminase 10 IU <i>E. coli</i> UP (8.7)	4 mM Phosphate buffer (pH 7.0)	864 (35)	-	14	[3]
2	Fludarabine	Ara-1Pi & 2F-Ado	<i>E. coli</i> PNP (360)	Water	3 (55)	94	77	[4]
3	Nelardbine	Ara-U & C <sup>6</sup> OMe- Guo (2:1, mol)	<i>E. coli</i> PNP (37,778) <i>E. coli</i> UP (1,889)	10 mM Phosphate buffer (pH 7.4)	18 (60)	-	53 (for base taken in the reaction)	[5]
4	Nelarabine	Ara-U & C <sup>6</sup> OMe- Guo (1.1:1, mol)	<i>E. coli</i> PNP (18,000) <i>E. coli</i> UP (1,020)	10 mM K-Pi buffer/n-PrOH (7% v/v; (pH 6.75)	624 (37)	-	17	[6]
5	Nelarabine	Chem.Ara-1Pi & C <sup>6</sup> OMe-Guo (ca. 5:1, mol)	<i>E. coli</i> PNP (49)	Water	36 (45)	50	40	[4]
6	Nelarabine	Ara-1Pi & C <sup>6</sup> OMe- Guo (ca. 1.7:1, mol)	<i>E. coli</i> PNP (ca. 1,400 prt Ara-1P & 2,333 per base)	Water	48 (47)	85	53 (HPLC purity 99.3%)	This study
7	Nelarabine (test experiment)	Ara-U & C <sup>6</sup> OMe- Guo (1.5:1, mol)	<i>E. coli</i> PNP (10,000) <i>E. coli</i> UP (5,000)	5 mM K-Pi buffer (pH 8.00)	1 (23)	Base to nucleoside <b>44%</b> Ara-U to Ara- 1Pi <b>≥95</b>	-	This study
8	Nelarabine	Crude Ara-1Pi & C <sup>6</sup> OMe-Guo (ca. 2:1, mol)	<i>E. coli</i> UP (516 per Ara-U) <i>E. coli</i> PNP (1,484 per base)	Water	1 <sup>st</sup> 72 (r.t.) 2 <sup>nd</sup> 120 (50-55)	1 <sup>st</sup> >95-97% 2 <sup>nd</sup> ca. 60%	52 (HPLC purity 99%)	This study
9	Ara-1Pi	Ara-U (170 mg, 0.7 mmol)	<i>E. coli</i> UP (150)	Water	72 (40)	≥97	96	This study
10	Rib-1Pi	Uridin (63 mg, 0.258 mmol)	<i>E. coli</i> UP (387)	Water	60 (23)	≥97	96	This study
11	Kinetin Riboside Not optimized!	Crude Ara-1Pi & C <sup>6</sup> OMe-Guo (ca. 2:1, mol)	<i>E. coli</i> UP (580) >95-97% <i>E. coli</i> PNP (342)	Water	1 <sup>st</sup> 72 (r.t.) 2 <sup>nd</sup> 144 (50)	1 <sup>st</sup> >95-97% 2 <sup>nd</sup> 72%	61 (HPLC purity 98%)	This study

12	Kinetin Riboside	Ara-1Pi & C <sup>6</sup> OMe-Guo (ca.2:1, mol)	<i>E. coli</i> PNP (263)	Tris HCl 50 mM	2 h (r.t.)	>95-97%	93% (HPLC purity 98.5%)	This study
13	N <sup>6</sup> -Benzyl-adenosine	Guanosine (1.5 + 0.5 mmol) & N <sup>6</sup> -BzAde (1 mmol)	<i>E. coli</i> PNP (120 IU; 80 & 120 units per Guo and base, respectively)	5 mM K-Pi buffer (pH 7.00)	20 + 6 h (40)	ca. 10% of base was recovered	67% (HPLC purity 99.2%)	This study
14	Cladribine	Dowex-nPi dRib-1Pi ----- dRib-1Pi & <sup>2</sup> ClAde (3: 1, mol)	<i>E. coli</i> UP (66.0) >95-97% ----- <i>E. coli</i> PNP (1,800 per base)	Water	120 h (40 °C) ----- 72 h (47 °C)	>95-97% ----- 88%	93% ----- -	This study
15	Cladribine	Thd (0.56 mmol) QAE Sephadex-nPi & dRib-1Pi + <sup>2</sup> ClAde (0.059 mmol)	<i>E. coli</i> UP (89.0) >95-97% ----- <i>E. coli</i> PNP (2,288 per base)	Water	120 h (40 °C) ----- 96 h (40 °C)	>95-97% ----- 81%	----- 59%	This study

## References and notes

1. Zinchenko, A. I.; Barai, V. N.; Lyakhovets, V. I.; Kulak, T. I.; Kvasyuk, E. I.; Mikhailopulo, I. A. *Russ. J. Bioorg. Chem.* **1988**, *14*, 1401–1404.
2. Kissman, H. M.; Weiss, M. J. *J. Org. Chem.* **1956**, *21*, 1053–1055. doi:10.1021/jo01115a621
3. Koszalka, G.W.; Averett, D.R.; Fyfe, J.A.; Roberts, G.B.; Spector, T.; Biron, K.; Krenitsky, T.A. *Antimicrob Agents Chemother.* **1991**, *35*(7), 1437-1443; doi: 10.1128/aac.35.7.1437
4. Konstantinova, I.D.; Antonov, K.V.; Fateev, I.V.; Miroshnikov, A.I.; Stepchenko, V.A.; Baranovsky, A.V.; Mikhailopulo, I.A. A Chemo-Enzymatic Synthesis of  $\beta$ -D-Arabinofuranosyl Purine Nucleosides. *Synthesis* **2011**, (10), 1555-1560; doi: 10.1055/s-0030-1260010.
5. Averett, D.R.; Koszalka, G.W.; Fyfe, J.A.; Roberts, G.B.; Purifoy, D.J.M. and Krenitsky, T.A. 6-Methoxypurinc arabinoside as a selective and potent inhibitor of varicella-zostervirus. *Antimicrob Agents Chemother.* **1991**, *35* (5), 851–857. doi: 10.1128/AAC.35.5.851.
6. Averett, D.R.; Jones, L.A.; Moorman, A. R.; Koszalka, G.W.; Krenitsky, Th.A. Antiviral compounds. EP 0 294 114 B1. 11.09.1996 Bulletin 1996/37; THE WELLCOME FOUNDATION Ltd. London NW1 2BP (GB); Priority: 30.05.1987 GB 8712745.